Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.50 |
| ▸ | STK17B | O94768 | 3/20 | 0.50 |
| ▸ | SYK | P43405 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13789065 | 0.84 | GSK3B (0.55) | STK17ASTK17BSYKEGFR | |
| SCHEMBL5405551 | 0.77 | STK17A (0.55) | STK17ASTK17BSYKEGFRCDK5 | |
| SCHEMBL4512217 | 0.74 | GSK3A (0.54) | — | |
| SCHEMBL4496644 | 0.72 | EGFR (0.50) | STK17ASTK17BEGFR | |
| SCHEMBL7241987 | 0.69 | CDK4 (0.74) | EGFRCDK5IGF1R | |
| SCHEMBL13794369 | 0.69 | AURKA (0.39) | STK17ASTK17BEGFR | |
| SCHEMBL10187807 | 0.69 | STK17A (0.61) | STK17ASTK17BSYKBRD4EGFR | |
| SCHEMBL29024862 | 0.67 | SYK (0.57) | STK17ASYKBRD4EGFRITK | |
| SCHEMBL20154831 | 0.67 | STK17A (1.00) | STK17ASTK17B | |
| SCHEMBL12519659 | 0.66 | EGFR (0.81) | EGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563781-B2 | Triazolopyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-21 | — | — | US | disclosed |
| US-7563781-B2 | Triazolopyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-21 | — | — | US | disclosed |
| US-20070015207-A1 | Triazolopyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015207-A1 | Triazolopyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015207-A1 | Triazolopyrimidine derivatives | ABL1, FLT3, ROS1 | STK17A 35/4885STK17B 10/4885SYK 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.